Feature | Heart Failure | July 17, 2015

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

Results support previous observation of dose-dependent signals across multiple endpoints

NeoStem, PreSERVE study, AMI, ACC.15, NBS10, CD34 stem cells

July 17, 2015 - NeoStem Inc. presented updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study and additional analyses of certain functional tests at the American College of Cardiology's 64th annual scientific session and expo in March. The one-year follow-up results are defined as all data accumulated until the last patient enrolled completed 12-month follow-up. Thus, the results actually represent data from patients with a median follow-up of 18 months.

NeoStem is developing CD34 cell-based therapies to address damage to tissue caused by ischemia. Ischemia occurs when the supply of oxygenated blood in the body is restricted. The company's Ischemic Repair Program seeks to reverse the damage caused by this restriction through the development and formation of new blood vessels. The program's lead product candidate in this area is NBS10, a chemotactic hematopoietic stem cell product comprised of autologous bone marrow-derived CD34/CXCR4 cells selected to treat damaged heart muscle following acute myocardial infarction (AMI).

One-year follow-up safety data collected thus far supports the trial's six-month results presented at the American Heart Association's scientific sessions in November 2014. The ACC presentation contained updated safety and exploratory efficacy data and additional analyses conducted on left ventricular ejection fraction (LVEF) data. 

Clinical Endpoint Committee adjudication of major adverse cardiac events (MACE) was performed on the six-month data reported previously and was not performed for new events (occurring between 6 and 12 months). The next prescribed adjudication of MACE is currently planned at the end of patient follow-up. At 12-month follow-up, no meaningful safety or tolerance differences were observed between treatment and control groups. In this updated analysis, no additional deaths were reported in the treatment or control groups beyond those previously reported in the six-month analysis.  In addition, in post hoc subset analyses based on the number of cells patients received, serious adverse event (SAE) frequency continues to show numerical improvement at all cell doses when compared to control. 

No additional single-photon emission computed tomography (SPECT) data were collected at one year follow-up. As an exploratory measure of efficacy, PreSERVE looked at reduction of infarct size at six months. Patients receiving 20 million cells or more experienced a decrease in infarct size of 41 percent versus 24 percent for patients in the control group.

Based on the one-year follow-up results, the company and its scientific advisors believe that the study results suggest:

  • Intracoronary administration of autologous CD34+ cells appears safe and well-tolerated;
  • A signal for a mortality benefit; and
  • A signal for reduction in the frequency of serious adverse events (SAEs) in higher dose groups.


"While small in number, we are encouraged by the fewer mortality events observed for treated patients versus control patients as of the date of this 12-month follow-up. In addition, we are very encouraged by the persistence of reduced serious adverse event rates and evidence for improved infarct healing and left ventricular function," said Arshed A. Quyyumi, M.D., professor of medicine at Emory University and lead principal investigator of the PreSERVE AMI study, who made the presentation at ACC.15. "In addition, the failure of SPECT imaging to document changes at the 6 month interim analysis, despite signs of clinical benefit in multiple parameters, suggests that this technique is not applicable in this setting."

For more information: www.neostem.com

Related Content

Guideline Adherence, Not Patient Volume, May Be Better Hospital Heart Failure Metric
News | Heart Failure | February 01, 2018
February 1, 2018 –  In evaluating the quality of care given to those hospitalized with...
First-in-Man RenalGuard Studies Show Promise for Heart Failure Patients
News | Heart Failure | January 02, 2018
RenalGuard Solutions Inc. reported positive results from a first-in-man feasibility study focusing on a novel use of...
ACC Issues New Guidance to Optimize Heart Failure Treatment
News | Heart Failure | December 22, 2017
December 22, 2017 — To help streamline treatment of patients with...
Coffee Associated With Reduced Risk of Heart Failure, Stroke. AHA 2017. #AHA2017
News | Heart Failure | November 25, 2017
November 25, 2017 — Drinking coffee may be associated with a decreased risk of developing heart failure or having str
Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years among U.S. veterans, according to preliminary research presented at the 2017 American Heart Association (AHA) Scientific Sessions.
News | Heart Failure | November 25, 2017
November 25, 2017 — Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years a
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure | November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure | November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Heart Failure | November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Scientists Reverse Advanced Heart Failure in Mouse Model
News | Heart Failure | October 30, 2017
October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart.
Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure | October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Overlay Init